Relationship between Subclinical Hypothyroidism and Uremic Pruritis in Hemodialysis Patients.

IF 2 4区 医学 Q3 ENDOCRINOLOGY & METABOLISM Endocrine, metabolic & immune disorders drug targets Pub Date : 2024-01-01 DOI:10.2174/1871530323666230509103021
Essam Kotb, Ismail Mohamed El Mancy, Ibrahim Ghounim Ramadan Mohamed, Hazem Sayed Ahmed Ayoub, Al-Sayed M Rashed, Waleed S El-Nasser, Hani Ismail Hamed, Hossam Aladl Aladl, Mostafa Sabrh, Ahmed Eliwa, Esam M Ghamry, Mohamed R Abdelhamed, Tamer M Mahmoud
{"title":"Relationship between Subclinical Hypothyroidism and Uremic Pruritis in Hemodialysis Patients.","authors":"Essam Kotb, Ismail Mohamed El Mancy, Ibrahim Ghounim Ramadan Mohamed, Hazem Sayed Ahmed Ayoub, Al-Sayed M Rashed, Waleed S El-Nasser, Hani Ismail Hamed, Hossam Aladl Aladl, Mostafa Sabrh, Ahmed Eliwa, Esam M Ghamry, Mohamed R Abdelhamed, Tamer M Mahmoud","doi":"10.2174/1871530323666230509103021","DOIUrl":null,"url":null,"abstract":"<p><strong>Background and aim: </strong>Uremic pruritus (UP) is one of the most distressing symptoms in hemodialysis (HD) patients. Subclinical hypothyroidism (SCH) is a biochemical condition with high prevalence in HD patients. The present multicentric study aimed to assess the relationship between UP and SCH in HD patients.</p><p><strong>Methods: </strong>The present cross-sectional study included 328 HD patients. All patients were submitted to careful history through clinical examination and standard laboratory assessment. Pruritis was evaluated using the pruritis visual analog scale (VAS). Patients were diagnosed with SCH if they had TSH levels above the upper limit of the normal reference range in association with normal free thyroxine (FT4) levels.</p><p><strong>Results: </strong>Among the studied patients, there were 196 patients (59.8 %) with UP. Comparison between patients with UP and patients without revealed that patients in the former group had significantly longer HD duration (median (IQR): 47.5 (27.0-72.5) versus 36.0 (23.0-50.5) months, p < 0.001) and lower Kt/v (median (IQR): 1.4 (1.09-1.7) versus 1.54 (1.12-1.91), p = 0.009). Moreover, they had significantly higher ferritin (median (IQR): 653.0 (526.0-800.0) versus 628.0 (470.8- 716.0) ng/mL), hsCRP (median (IQR): 12.0 (8.0-14.0) versus 8.0 (6.0-9.0) mg/dL, p < 0.001) and TSH levels (median (IQR): 4.34 (1.98-5.2) versus 3.34 (1.9-4.85) μIU/ml) with a significantly higher frequency of SCH (45.9 % versus 28.8 %, p = 0.002). Logistic regression analysis identified hemodialysis duration (OR (95%) CI): 1.02 (1.009-1.028), p < 0.001), ferritin levels (OR (95% CI): 1.002 (1.001-1.003), p < 0.001), and SCH (OR (95% CI): 0.54 (0.32-0.89), p = 0.016) as significant predictors of UP.</p><p><strong>Conclusion: </strong>The present study suggested a possible link between SCH and the development of UP in HD patients.</p>","PeriodicalId":11614,"journal":{"name":"Endocrine, metabolic & immune disorders drug targets","volume":" ","pages":"235-241"},"PeriodicalIF":2.0000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Endocrine, metabolic & immune disorders drug targets","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2174/1871530323666230509103021","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

Abstract

Background and aim: Uremic pruritus (UP) is one of the most distressing symptoms in hemodialysis (HD) patients. Subclinical hypothyroidism (SCH) is a biochemical condition with high prevalence in HD patients. The present multicentric study aimed to assess the relationship between UP and SCH in HD patients.

Methods: The present cross-sectional study included 328 HD patients. All patients were submitted to careful history through clinical examination and standard laboratory assessment. Pruritis was evaluated using the pruritis visual analog scale (VAS). Patients were diagnosed with SCH if they had TSH levels above the upper limit of the normal reference range in association with normal free thyroxine (FT4) levels.

Results: Among the studied patients, there were 196 patients (59.8 %) with UP. Comparison between patients with UP and patients without revealed that patients in the former group had significantly longer HD duration (median (IQR): 47.5 (27.0-72.5) versus 36.0 (23.0-50.5) months, p < 0.001) and lower Kt/v (median (IQR): 1.4 (1.09-1.7) versus 1.54 (1.12-1.91), p = 0.009). Moreover, they had significantly higher ferritin (median (IQR): 653.0 (526.0-800.0) versus 628.0 (470.8- 716.0) ng/mL), hsCRP (median (IQR): 12.0 (8.0-14.0) versus 8.0 (6.0-9.0) mg/dL, p < 0.001) and TSH levels (median (IQR): 4.34 (1.98-5.2) versus 3.34 (1.9-4.85) μIU/ml) with a significantly higher frequency of SCH (45.9 % versus 28.8 %, p = 0.002). Logistic regression analysis identified hemodialysis duration (OR (95%) CI): 1.02 (1.009-1.028), p < 0.001), ferritin levels (OR (95% CI): 1.002 (1.001-1.003), p < 0.001), and SCH (OR (95% CI): 0.54 (0.32-0.89), p = 0.016) as significant predictors of UP.

Conclusion: The present study suggested a possible link between SCH and the development of UP in HD patients.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
血液透析患者亚临床甲状腺机能减退与尿毒症性瘙痒症之间的关系
背景和目的:尿毒症性瘙痒(UP)是血液透析(HD)患者最痛苦的症状之一。亚临床甲状腺功能减退症(SCH)是一种生化疾病,在血液透析患者中发病率很高。本项多中心研究旨在评估血液透析患者甲状腺机能减退与甲状腺机能减退之间的关系:本横断面研究包括 328 名 HD 患者。所有患者均通过临床检查和标准实验室评估仔细询问病史。使用瘙痒症视觉模拟量表(VAS)评估瘙痒症。如果患者的促甲状腺激素(TSH)水平高于正常参考值范围的上限,同时游离甲状腺素(FT4)水平正常,则被诊断为SCH:在研究的患者中,196 名患者(59.8%)患有甲状腺功能减退症。对比发现,前一组患者的 HD 持续时间明显更长(中位数(IQR):47.5(27.0-72.5)个月对 36.0(23.0-50.5)个月,p < 0.001),Kt/v 明显更低(中位数(IQR):1.4(1.09-1.7)个月对 1.54(1.12-1.91)个月,p = 0.009)。此外,他们的铁蛋白(中位数(IQR):653.0(526.0-800.0)对 628.0(470.8- 716.0)纳克/毫升)、hsCRP(中位数(IQR):12.0(8.0-14.0)对 8.0(6.0-9.0)mg/dL,p < 0.001)和 TSH 水平(中位数(IQR):4.34(1.98-5.2)对 3.34(1.9-4.85)μIU/ml),其中 SCH 的频率明显更高(45.9% 对 28.8%,p = 0.002)。逻辑回归分析发现,血液透析持续时间(OR (95%) CI):1.02 (1.009-1.028),p < 0.001)、铁蛋白水平(OR (95% CI):1.002 (1.001-1.003),p < 0.001)和SCH(OR (95% CI):0.54 (0.32-0.89),p = 0.016)是UP的重要预测因素:本研究表明,SCH与HD患者发生UP之间可能存在联系。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Endocrine, metabolic & immune disorders drug targets
Endocrine, metabolic & immune disorders drug targets ENDOCRINOLOGY & METABOLISMIMMUNOLOGY-IMMUNOLOGY
CiteScore
4.60
自引率
5.30%
发文量
217
期刊介绍: Aims & Scope This journal is devoted to timely reviews and original articles of experimental and clinical studies in the field of endocrine, metabolic, and immune disorders. Specific emphasis is placed on humoral and cellular targets for natural, synthetic, and genetically engineered drugs that enhance or impair endocrine, metabolic, and immune parameters and functions. Moreover, the topics related to effects of food components and/or nutraceuticals on the endocrine-metabolic-immune axis and on microbioma composition are welcome.
期刊最新文献
WITHDRAWN: Evaluation and Association of Hematological and Biochemical Parameters of Untreated COVID-19 Patients on the basis of Differences in Ethnicity and Curcumin as a Possible Treatment Single-Cell RNA Sequencing Reveals Transcriptional Signatures and Cell-Cell Communication in Diabetic Retinopathy Current Developments in the Prevention and Improvement of Intestinal Disorders: A Mini-Review Clinical Presentation, Diagnosis, and Management of Hyperinsulinemic Hypoglycemia in Adults: A Single-center Experience Diabulimia and Type 1 Diabetes: An Unknown and Emerging Problem
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1